Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Trial Profile

Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ABSORB-LONG
  • Most Recent Events

    • 16 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top